A Clinical Trial to Evaluate the Effects of a Plant-Based Liquid Supplement on Metabolic Health and Overall Well-Being
2026年6月23日 更新者:Biocol Labs
This single-arm clinical trial will evaluate the effects of a plant-based liquid supplement on metabolic health, digestive health, skin health, and overall well-being.
Twenty participants aged 40 to 60 years with elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels will use the supplement daily for 90 days.
Participants will complete questionnaires, provide body composition and waist circumference measurements, submit photographs, and undergo blood testing throughout the study.
Outcomes include changes in metabolic biomarkers, body composition, digestive symptoms, skin health, and overall well-being.
研究概览
研究类型
介入性
注册 (实际的)
20
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Nevada
-
Las Vegas、Nevada、美国、89118
- Citruslabs
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
不
描述
Inclusion Criteria:
- Age 40 to 60 years
- Elevated ALT or AST identified during prescreening blood testing
- Currently experiencing at least two of the following:
Stomach discomfort, Constipation, Diarrhea, Heartburn, Bloating, Gas, Abdominal pain, Skin redness or pimples, Sugar cravings
- Willing to comply with study requirements
- Willing to discontinue supplements or herbal remedies targeting detoxification, digestive health, liver function, or skin health during the study
- Willing to avoid starting new products, medications, or supplements targeting detoxification, digestive health, liver function, or skin health
- Willing to maintain normal diet, sleep patterns, and activity levels
- Generally healthy without uncontrolled chronic disease
- Resides in the United States
- Not participating in another research study during the study period
- Has access to a study partner to take study photographs
Exclusion Criteria:
- Severe digestive disorders including acid reflux, IBS, IBD, Crohn's disease, or gastrointestinal tract surgeries
- Liver disease
- Known allergy or hypersensitivity to study product ingredients Chronic conditions that would interfere with study participation, including oncological or psychiatric disorders
- Known severe allergic reactions
- Pregnant, breastfeeding, or attempting to conceive
- Unwilling to follow study procedures
- Stopped hormonal birth control within the past month
- History of substance abuse
- Use of prescription diabetes medications, including GLP-1 receptor agonists such as Ozempic, Wegovy, or Mounjaro
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Plant-Based Liquid Supplement
Participants will consume one ampule of the study product diluted in approximately 8 ounces of water before the first meal of the day throughout the study period.
|
A liquid dietary supplement containing choline bitartrate, zinc sulfate, manganese sulfate, artichoke leaf extract, fennel extract, rosemary leaf extract, L-arginine monohydrochloride, inositol, bromelain, papain, sorbitol, glycerin, artificial flavour, and potassium sorbate.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Body Weight
大体时间:Baseline, Day 30, Day 60, and Day 90.
|
Change in body weight measured using a Withings smart scale.
|
Baseline, Day 30, Day 60, and Day 90.
|
|
Change in Waist Circumference
大体时间:Baseline, Day 7, Day 30, Day 60, and Day 90.
|
Change in waist circumference measured using a tape measure and recorded in centimeters.
|
Baseline, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Body Fat Mass
大体时间:Baseline, Day 7, Day 30, Day 60, and Day 90.
|
Change in body fat mass measured using a Withings smart scale.
|
Baseline, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Lean Body Mass
大体时间:Baseline, Day 7, Day 30, Day 60, and Day 90.
|
Change in lean body mass measured using a Withings smart scale.
|
Baseline, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Visceral Fat Index
大体时间:Baseline, Day 7, Day 30, Day 60, and Day 90.
|
Change in visceral fat index measured using a Withings smart scale.
|
Baseline, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Alanine Aminotransferase (ALT)
大体时间:Baseline, Day 30, Day 60, and Day 90.
|
Change in serum alanine aminotransferase concentration measured by hepatic function panel.
|
Baseline, Day 30, Day 60, and Day 90.
|
|
Change in Aspartate Aminotransferase (AST)
大体时间:Baseline, Day 30, Day 60, and Day 90
|
Change in serum aspartate aminotransferase concentration measured by hepatic function panel.
|
Baseline, Day 30, Day 60, and Day 90
|
|
Change in Alkaline Phosphatase (ALP)
大体时间:Baseline, Day 30, Day 60, and Day 90.
|
Change in serum alkaline phosphatase concentration measured by hepatic function panel.
|
Baseline, Day 30, Day 60, and Day 90.
|
|
Change in Total Bilirubin
大体时间:Baseline, Day 30, Day 60, and Day 90.
|
Change in serum total bilirubin concentration measured by hepatic function panel.
|
Baseline, Day 30, Day 60, and Day 90.
|
|
Change in Total Cholesterol
大体时间:Baseline, Day 30, Day 60, and Day 90.
|
Change in serum total cholesterol concentration measured by lipid panel.
|
Baseline, Day 30, Day 60, and Day 90.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Participant-Reported Bloating Severity
大体时间:Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
Change in participant-reported bloating severity assessed by study questionnaire.
|
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Participant-Reported Flatulence Severity
大体时间:Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
Change in participant-reported flatulence severity assessed by study questionnaire.
|
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Participant-Reported Heartburn Severity
大体时间:Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
Change in participant-reported heartburn severity assessed by study questionnaire.
|
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Participant-Reported Digestive Comfort
大体时间:Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
Change in participant-reported digestive comfort assessed by study questionnaire.
|
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
|
Change in Participant-Reported Skin Health
大体时间:Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
Change in participant-reported skin health assessed by study questionnaire.
|
Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
合作者
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2025年6月5日
初级完成 (实际的)
2026年1月15日
研究完成 (实际的)
2026年1月15日
研究注册日期
首次提交
2026年6月23日
首先提交符合 QC 标准的
2026年6月23日
首次发布 (实际的)
2026年6月29日
研究记录更新
最后更新发布 (实际的)
2026年6月29日
上次提交的符合 QC 标准的更新
2026年6月23日
最后验证
2026年6月1日
更多信息
与本研究相关的术语
其他研究编号
- #20758
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.